Abstract
Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Current Pharmaceutical Design
Title: Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder
Volume: 18 Issue: 4
Author(s): A. Bechdolf, A. Ratheesh, S. J. Wood, T. Tecic, P. Conus, B. Nelson, S. M. Cotton, A. M. Chanen, G. P. Amminger, S. Ruhrmann, F. Schultze-Lutter, J. Klosterkotter, P. Fusar Poli, A. R. Yung, M. Berk and P. D. McGorry
Affiliation:
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Abstract: Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Export Options
About this article
Cite this article as:
Bechdolf A., Ratheesh A., J. Wood S., Tecic T., Conus P., Nelson B., M. Cotton S., M. Chanen A., P. Amminger G., Ruhrmann S., Schultze-Lutter F., Klosterkotter J., Fusar Poli P., R. Yung A., Berk M. and D. McGorry P., Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316226
DOI https://dx.doi.org/10.2174/138161212799316226 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Cardioprotective Effects of Indian Gooseberry (Emblica officinalis Gaertn) and its Phytochemicals: A Review
Current Nutrition & Food Science Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews Therapeutic Implications of Beta-Adrenergic Receptor Pharmacodynamic Properties
Current Clinical Pharmacology MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Thyrotoxic Periodic Paralysis: A Concise Review of the Literature
Current Rheumatology Reviews Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics Patent Selections
Recent Patents on DNA & Gene Sequences Current Place of Beta-Blockers in the Treatment of Hypertension
Current Vascular Pharmacology Atherosclerotic Plaque Detection by Multi-detector Computed Tomography
Current Cardiology Reviews